Ranolazine dihydrochloride

Names

[ Name ]:
Ranolazine dihydrochloride

[Synonym ]:
Ranolazine dihydrochloride
RANOLAZINE HCL
MFCD03788770
RANOLAZINE DI HCL
Ranolazine (dihydrochloride)
N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazinyl}acetamide dihydrochloride
Ranolazine DiHCI
Ranolazine and salt
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, hydrochloride (1:2)
Ranolazine Dihydrocloride
Ranolazine 2HCl
N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide dihydrochloride
Ranolazine dihydroch

Biological Activity

[Description]:

Ranolazine(RS-43285) is an antianginal agent with antiarrhythmic properties that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). IC50 value:Target: sodium-dependent calcium channelRanolazine is currently approved for use in chronic angina. The basis for this use is likely related to inhibition of late sodium channels with resultant beneficial downstream effects. Randomized clinical trials have demonstrated an improvement in exercise capacity and reduction in angina episodes with ranolazine.

[Related Catalog]:

Signaling Pathways >> Autophagy >> Autophagy

Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel

Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel

Research Areas >> Cardiovascular Disease

[References]

[1]. Hawwa N, Menon V. Ranolazine: Clinical Applications and Therapeutic Basis. Am J Cardiovasc Drugs. 2013 Jan 19.

[2]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73.

[3]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.

[4]. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008 Mar;153(6):1128-32. Epub 2007 Dec 10.

[5]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
624.1ºC at 760 mmHg

[ Melting Point ]:
222-229.5ºC(lit.)

[ Molecular Formula ]:
C₂₄H₃₅Cl₂N₃O₄

[ Molecular Weight ]:
500.458

[ Exact Mass ]:
499.200470

[ PSA ]:
74.27000

[ LogP ]:
3.86080

[ Appearance of Characters ]:
solid | off-white

[ Storage condition ]:
Desiccate at RT

[ Water Solubility ]:
H2O: 10 mg/mL, soluble

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Safety Phrases ]:
S22-S24/25

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ HS Code ]:
2942000000

Customs

[ HS Code ]: 2942000000

Articles

Regulation of Hyaluronan (HA) Metabolism Mediated by HYBID (Hyaluronan-binding Protein Involved in HA Depolymerization, KIAA1199) and HA Synthases in Growth Factor-stimulated Fibroblasts.

J. Biol. Chem. 290 , 30910-23, (2015)

Regulation of hyaluronan (HA) synthesis and degradation is essential to maintenance of extracellular matrix homeostasis. We recently reported that HYBID (HYaluronan-Binding protein Involved in hyaluro...